Gilead's MAA for Biktarvy to treat HIV─1 infection receives positive opinion from EMA committee

16:56 EDT 30 Apr 2018 | PharmaBiz

Gilead Sciences, Inc. announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the company's Marketing Authorization Application (MAA) for Biktarvy

More From BioPortfolio on "Gilead's MAA for Biktarvy to treat HIV─1 infection receives positive opinion from EMA committee"